BENGALURU — In a major breakthrough for global public health, researchers from the Centre for Ecological Sciences at the Indian Institute of Science, in partnership with scientists at the Technical University of Denmark, have developed a synthetic antivenom that provides broad-spectrum protection against venom from geographically diverse cobra and king cobra species across India. The findings, published in the prestigious journal Science Translational Medicine, offer a viable solution to modernise a medical treatment that has remained essentially unchanged for over a century.
India remains the world’s hardest-hit nation regarding snake envenomation, recording over 50,000 fatalities annually alongside tens of thousands of permanent disabilities. Historically, addressing this crisis has been stymied by the sheer complexity of snake venom, as individual species produce unique chemical cocktails of toxins that attack nerve tissue, blood vessels, and vital organs. Conventional treatments still rely on century-old methods involving the milking of live venom and repeated immunization of horses or sheep to harvest serum. This labour-intensive procedure yields low concentrations of therapeutic antibodies while frequently causing adverse allergic reactions, batch inconsistency, and limited efficacy outside narrow geographical areas.
To overcome these historical limitations, the international research team engineered an advanced recombinant antibody therapy without animal exploitation. Drawing from previous work involving camelids like alpacas and llamas, the scientists utilized microbial host cells to culture and produce targeted antibody fragments called nanobodies. By screening these fragments through phage display techniques, the researchers assembled an optimized cocktail composed of five engineered nanobodies capable of binding directly to toxic proteins found across various Indian elapid snakes.
Preclinical trials yielded remarkable therapeutic results in animal models. The antibody cocktail successfully neutralized toxins from the common spectacled cobra, monocled cobra, and two distinct Indian king cobra species, effectively preventing the venom molecules from docking onto their cellular targets. In laboratory mice, the formulation prevented mortality even when administered a full thirty minutes post-envenomation, fully reversing visible neurotoxic symptoms and severe muscular paralysis. Because the engineered nanobodies demonstrate high therapeutic potency in minute doses, the team anticipates the treatment will drastically lower manufacturing costs, improve patient safety, and establish a flexible blueprint for developing region-specific antivenoms worldwide.
